17.35

7.11% -1.57

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $17.35, with a volume of 1.30M. It is down -7.11% in the last 24 hours and down -14.56% over the past month. Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Previous Close:

$18.92

Open:

$18.76

24h Volume:

1.30M

Relative Volume:

0.43

Market Cap:

$860.29M

Revenue:

$27.10M

Net Income/Loss:

$-24.31M

P/E Ratio:

-14.83

EPS:

-1.17

Net Cash Flow:

$-33.33M

1W Performance:

-4.95%

1M Performance:

-14.56%

6M Performance:

+179.41%

1Y Performance:

+501.88%

1-Day Range:

$17.02

$20.03

1-Week Range:

$17.02

$20.03

52-Week Range:

$2.90

$23.40

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(310) 358-3200

Address

8840 WILSHIRE BLVD, BEVERLY HILLS, CA

Employee

102

Twitter

@Capricor

Next Earnings Date

2024-11-12

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR	17.35	860.29M	27.10M	-24.31M	-33.33M	-1.17
VRTX	448.30	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.33	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	590.79	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.38	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.62	24.49B	3.30B	-501.07M	1.03B	11.54

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

Nov 20, 2024

Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha

Nov 20, 2024

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times

Nov 20, 2024

Nov 18, 2024

(CAPR) Proactive Strategies - Stock Traders Daily

Nov 18, 2024

Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada

Nov 18, 2024

HC Wainwright Brokers Increase Earnings Estimates for CAPR - MarketBeat

Nov 18, 2024

Nov 16, 2024

Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat

Nov 16, 2024

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 15, 2024